Loading...
•
Mar 31, 2022
Innoviva Q1 2022 Earnings Report
Reported financial results with royalty revenues growing 5% year over year, driven by strong positive momentum.
Key Takeaways
Innoviva reported its Q1 2022 financial results, highlighting a 5% year-over-year growth in royalty revenues. The company saw growth in TRELEGY® ELLIPTA® global net sales, offset by a decrease in ANORO® ELLIPTA® global net sales. Innoviva also consolidated Entasis financials and refinanced debt, which impacted reported income.
Royalty revenues increased by 5% year-over-year.
RELVAR®/BREO® ELLIPTA® global net sales decreased slightly, with U.S. growth compensating for non-U.S. slowdown.
TRELEGY® ELLIPTA® global net sales increased by 33% compared to Q1 2021.
Consolidated Entasis financials and refinanced debt, impacting reported income.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...